4.3 Article

Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer

期刊

ONCOTARGET
卷 6, 期 14, 页码 12369-12382

出版社

IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.3682

关键词

MDSC; CRC; arginase-1; inducible nitric oxide synthase; GM-CSF

资金

  1. Interuniversity Attraction Poles Program-Belgian State-Belgian Science Policy
  2. National Cancer Plan of the Federal Ministry of Health
  3. Stichting tegen Kanker
  4. Vlaamse Liga tegen Kanker, an Integrated Project
  5. EU
  6. IWT-TBM program
  7. FWO-Vlaanderen
  8. Scientific Fund Willy Gepts of the University Hospital Brussels
  9. IWT
  10. University College London Overseas PhD Scholarship
  11. Arthritis Research UK Career Development Fellowship [18433]
  12. Instituto de Salud Carlos III, Spain
  13. VLK

向作者/读者索取更多资源

Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of cells that accumulate in tumor-bearing subjects and which strongly inhibit anticancer immune responses. To study the biology of MDSC in colorectal cancer (CRC), we cultured bone marrow cells in conditioned medium from CT26 cells, which are genetically modified to secrete high levels of granulocyte-macrophage colony-stimulating factor. This resulted in the generation of high numbers of CD11b(+) Ly6G(+) granulocytic and CD11b(+) Ly6C(+) monocytic MDSC, which closely resemble those found within the tumor but not the spleen of CT26 tumor-bearing mice. Such MDSC potently inhibited T-cell responses in vitro, a process that could be reversed upon blocking of arginase-1 or inducible nitric oxide synthase (iNOS). We confirmed that inhibition of arginase-1 or iNOS in vivo resulted in the stimulation of cytotoxic T-cell responses. A delay in tumor growth was observed upon functional repression of both enzymes. These data confirm the role of MDSC as inhibitors of T-cell-mediated immune responses in CRC. Moreover, MDSC differentiated in vitro from bone marrow cells using conditioned medium of GM-CSF-secreting CT26 cells, represent a valuable platform to study/identify drugs that counteract MDSC activities.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Immunology

TNF-α-Secreting Lung Tumor-Infiltrated Monocytes Play a Pivotal Role During Anti-PD-L1 Immunotherapy

Kirsten De Ridder, Hanne Locy, Elisa Piccioni, Miren Ibarra Zuazo, Robin Maximilian Awad, Stefaan Verhulst, Mathias Van Bulck, Yannick De Vlaeminck, Quentin Lecocq, Eva Reijmen, Wout De Mey, Lien De Beck, Thomas Ertveldt, Isabel Pintelon, Jean-Pierre Timmermans, David Escors, Marleen Keyaerts, Karine Breckpot, Cleo Goyvaerts

Summary: Immune checkpoint blockade of the PD-1 pathway has greatly improved the survival prognosis for advanced non-small cell lung cancer (NSCLC). However, many PD-L1(+) NSCLC patients are resistant to anti-PD-L1 therapy. This study found that PD-L1(+) tumor-infiltrating myeloid cells play a crucial role in the failure of therapy. Anti-PD-L1 therapy induced a monocyte-specific production and response to TNF-alpha, accompanied by increased expression of CD80, VISTA, LAG-3, SIRP-alpha, and TIM-3. However, co-blockade of PD-L1 and TNF-alpha did not reduce tumor growth.

FRONTIERS IN IMMUNOLOGY (2022)

Review Biology

CAR-T Cells for the Treatment of Lung Cancer

Luisa Chocarro, Hugo Arasanz, Leticia Fernandez-Rubio, Ester Blanco, Miriam Echaide, Ana Bocanegra, Lucia Teijeira, Maider Garnica, Idoia Morilla, Maite Martinez-Aguillo, Sergio Pineiro-Hermida, Pablo Ramos, Juan Jose Lasarte, Ruth Vera, Grazyna Kochan, David Escors

Summary: Adoptive cell therapy with genetically modified T lymphocytes that express chimeric antigen receptors (CAR-T) has shown promising outcomes in treating hematological malignancies, but its efficacy in solid tumors is still unsatisfactory due to the immunosuppressive tumor microenvironment. Developing personalized CAR-T cells and identifying therapeutic targets are necessary to improve the treatment of solid tumors.

LIFE-BASEL (2022)

Article Oncology

Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer

Hugo Arasanz, Ana Isabel Bocanegra, Idoia Morilla, Joaquin Fernandez-Irigoyen, Maite Martinez-Aguillo, Lucia Teijeira, Maider Garnica, Ester Blanco, Luisa Chocarro, Karina Ausin, Miren Zuazo, Gonzalo Fernandez-Hinojal, Miriam Echaide, Leticia Fernandez-Rubio, Sergio Pineiro-Hermida, Pablo Ramos, Laura Mezquita, David Escors, Ruth Vera, Grazyna Kochan

Summary: This study investigated the role of baseline circulating low-density neutrophils (LDN) in NSCLC patients, identifying LDN as a predictive biomarker for immunotherapy resistance. Combining immunotherapy with chemotherapy can reduce LDN levels, overcome resistance, and suggest potential drug combinations for improved outcomes.

CANCERS (2022)

Review Cell Biology

Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor

Luisa Chocarro, Ana Bocanegra, Ester Blanco, Leticia Fernandez-Rubio, Hugo Arasanz, Miriam Echaide, Maider Garnica, Pablo Ramos, Sergio Pineiro-Hermida, Ruth Vera, David Escors, Grazyna Kochan

Summary: Immune checkpoint inhibitors (ICIs) have revolutionized oncology practice, with Lymphocyte-Activation Gene 3 (LAG-3) being a key next-generation immune checkpoint molecule. Clinical trials have shown positive results for LAG-3 targeting molecules. The recent FDA approval of a dual anti-PD-1 and anti-LAG-3 treatment has significantly improved progression-free survival.
Review Biochemistry & Molecular Biology

Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid Tumors

Ester Blanco, Luisa Chocarro, Leticia Fernandez-Rubio, Ana Bocanegra, Hugo Arasanz, Miriam Echaide, Maider Garnica, Sergio Pineiro-Hermida, Grazyna Kochan, David Escors

Summary: Immunotherapies based on immune checkpoint blockade have shown promising clinical outcomes but lack efficacy in most cancer patients. Intratumor delivery of monoclonal antibodies (mAbs) has emerged as a potential solution to reduce adverse events and improve treatment efficacy. Gene therapy vectors expressing mAbs inside tumors offer an attractive approach for local intratumor delivery. This expanding research subject will likely play a key role in future oncology.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Oncology

Lung-Heart Outcomes and Mortality through the 2020 COVID-19 Pandemic in a Prospective Cohort of Breast Cancer Radiotherapy Patients

Vincent Vinh-Hung, Olena Gorobets, Nele Adriaenssens, Hilde Van Parijs, Guy Storme, Dirk Verellen, Nam P. Nguyen, Nicolas Magne, Mark De Ridder

Summary: This study observed the follow-up of 123 women with stage I-II breast cancer who underwent adjuvant radiotherapy for over 10 years. The study found that there was higher mortality in 2020, with an increase in lung-heart toxicity and a decline in lung-heart function.

CANCERS (2022)

Review Biochemistry & Molecular Biology

Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer

Hugo Arasanz, Luisa Chocarro, Leticia Fernandez-Rubio, Ester Blanco, Ana Bocanegra, Miriam Echaide, Ibone Labiano, Ana Elsa Huerta, Maria Alsina, Ruth Vera, David Escors, Grazyna Kochan

Summary: Bispecific antibodies hold promise as a therapy for cancer, demonstrating the ability to simultaneously inhibit multiple proteins involved in cancer progression. In lung cancer treatment, their development has been particularly intense due to extensive knowledge of underlying molecular pathways, especially in oncogene-driven tumors. This review provides an overview of the current landscape of bispecific antibodies in lung cancer treatment and discusses potential future expansion of their role.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Review Oncology

Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events

Inigo Les, Mireia Martinez, Ines Perez-Francisco, Maria Cabero, Lucia Teijeira, Virginia Arrazubi, Nuria Torrego, Ana Campillo-Calatayud, Inaki Elejalde, Grazyna Kochan, David Escors

Summary: Immune-checkpoint inhibitors (ICIs) are widely used in cancer treatment, but they can cause immune-related adverse events (irAEs) in a significant number of patients. Predicting irAEs has become important for managing patients on ICIs. This review discusses biomarkers that have shown potential for predicting irAEs, including those already available for clinical use and those under investigation. Although these biomarkers have not been validated in prospective studies, there is growing evidence supporting their use for predicting and characterizing irAEs, which depend on factors such as the type of cancer, ICI agent, and affected organ. Further research is needed to understand the mechanisms of irAEs and to assess the predictive capacity of different biomarkers.

CANCERS (2023)

Review Geriatrics & Gerontology

Heat shock proteins and cellular senescence in humans: A systematic review

Mariam Hebishy, Cabirou Mounchili Shintouo, Ines Dufait, Florence Debacq-Chainiaux, Ivan Bautmans, Rose Njemini

Summary: Cellular senescence is a permanent arrest of cell growth and has important roles in tumor suppression, wound healing, tissue regeneration, and prevention of tissue fibrosis. The relationship between Heat Shock Proteins (HSP) and cellular senescence in humans lacks comprehensive investigation. This systematic review summarizes the literature on the prospective role of HSP in the development of cellular senescence in humans.

ARCHIVES OF GERONTOLOGY AND GERIATRICS (2023)

Article Biochemistry & Molecular Biology

Plasma fractalkine contributes to systemic myeloid diversity and PD-L1/PD-1 blockade in lung cancer

Ana Bocanegra, Gonzalo Fernandez-Hinojal, Daniel Ajona, Ester Blanco, Miren Zuazo, Maider Garnica, Luisa Chocarro, Elvira Alfaro-Arnedo, Sergio Pineiro-Hermida, Pilar Morente, Leticia Fernandez, Ana Remirez, Miriam Echaide, Maite Martinez-Aguillo, Idoia Morilla, Beatriz Tavira, Alejandra Roncero, Carolina Gotera, Alfonso Ventura, Nerea Recalde, Jose G. Pichel, Juan Jose Lasarte, Luis Montuenga, Ruth Vera, Ruben Pio, David Escors, Grazyna Kochan

Summary: Recent studies show that baseline functional immunity is crucial for the success of immune checkpoint blockade therapies. In this study, high-dimensional systemic immune profiling was performed on non-small-cell lung cancer patients undergoing PD-L1/PD-1 blockade immunotherapy. Responders had a higher diversity of myeloid phenotypes in their peripheral blood. A diversity index was defined as a potential biomarker of response. Fractalkine (FKN), a chemokine linked to immune chemotaxis and adhesion, was identified as a biomarker of response and correlated with myeloid cell diversity. FKN inhibited lung adenocarcinoma growth in both human and mouse models through the involvement of systemic effector NK cells and increased tumor immune infiltration. FKN also sensitized mouse lung cancer models resistant to anti-PD-1 treatment to immunotherapy, indicating its potential therapeutic use in combination with immunotherapy.

EMBO REPORTS (2023)

Article Oncology

Preoperative Radiotherapy with a Simultaneous Integrated Boost Compared to Chemoradiotherapy for cT3-4 Rectal Cancer: Long-Term Results of a Multicenter Randomized Study

Benedikt Engels, Antonino De Paoli, Elena Delmastro, Fernando Munoz, Stefano Vagge, Darius Norkus, Hendrik Everaert, Gianna Tabaro, Elisabetta Gariboldi, Umberto Ricardi, Eugenio Borsatti, Pietro Gabriele, Roberto Innocente, Elisa Palazzari, Emilie Dubaere, Marc-Andre Mahe, Sven Van Laere, Thierry Gevaert, Mark De Ridder

Summary: This study compared the efficacy of standard chemoradiotherapy and radiotherapy with a simultaneous integrated boost (SIB) for rectal cancer. The results showed no significant difference between the two treatments in terms of primary and secondary endpoints. SIB can be considered as a treatment option for T3-4 rectal cancer patients who are unable to tolerate chemotherapy.

CANCERS (2023)

Article Endocrinology & Metabolism

Metabolic rewiring induced by ranolazine improves melanoma responses to targeted therapy and immunotherapy

Marta Redondo-Munoz, Francisco Javier Rodriguez-Baena, Paula Aldaz, Adria Caballe-Mestres, Veronica Moncho-Amor, Maddalen Otaegi-Ugartemendia, Estefania Carrasco-Garcia, Ana Olias-Arjona, Irene Lasheras-Otero, Eva Santamaria, Ana Bocanegra, Luisa Chocarro, Abby Grier, M. Monika Dzieciatkowska, Claudia Bigas, Josefina Martin, Uxue Urdiroz-Urricelqui, Florencio Marzo, Enrique Santamaria, Grazyna Kochan, David Escors, Ignacio Marcos Larrayoz, Holger Heyn, Angelo D'Alessandro, Camille Stephan-Otto Attolini, Ander Matheu, Claudia Wellbrock, Salvador Aznar Benitah, Berta Sanchez-Laorden, Imanol Arozarena

Summary: In this study, the anti-anginal drug ranolazine is found to sensitize BRAF inhibitor-resistant melanoma to targeted therapy and immunotherapy by rewiring fatty acid oxidation and the methionine salvage pathway. Resistance of melanoma to targeted therapy and immunotherapy is linked to metabolic rewiring.

NATURE METABOLISM (2023)

Article Engineering, Electrical & Electronic

Interpretability and Repeatability of Radiomic Features: Applied on In Vivo Tumor Models

Amir L. Rifi, Ines Dufait, Chaimae El Aisati, Mark De Ridder, Kurt Barbe

Summary: Radiomic features are important for predicting tumor grade and treatment response, however their lack of interpretability hinders clinical application. This study proposes an innovative approach to correlate biological meaning to specific radiomic features using in vivo experiments. The results show that the radiomic features allow for distinguishable differences between tumor models and display high repeatability, indicating the feasibility of this approach in routine clinical practice.

IEEE TRANSACTIONS ON INSTRUMENTATION AND MEASUREMENT (2023)

Article Biology

Characterization of the long-term effects of lethal total body irradiation followed by bone marrow transplantation on the brain of C57BL/6 mice

P. Janssen, L. De Pauw, M. Mambretti, O. Lara, J. Walckiers, L. Mackens, I. Rooman, B. Guillaume, M. De Ridder, G. Ates, A. Massie

Summary: TBI followed by BMT had long-term impact on weight and locomotion but minimal effect on anxiety and depressive behavior. Impaired neurogenesis and cortical microglia activation were observed after TBI/BMT, and increased BBB permeability potentially contributed to the memory deficit.

INTERNATIONAL JOURNAL OF RADIATION BIOLOGY (2023)

暂无数据